Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clementia Pharmaceuticals Inc.

Division of Ipsen
www.clementiapharma.com

Latest From Clementia Pharmaceuticals Inc.

New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program

Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.

Orthopedics Clinical Trials

Ipsen Upbeat Despite Palovarotene Pain

The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.

Sales & Earnings Rare Diseases

Blow To Ipsen As FerGene Nabs CEO Meek

The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.

Appointments Leadership

Ipsen’s Palovarotene Hit By FDA Clinical Hold

The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.

Clinical Trials Safety
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • Clarissa Desjardins, PhD, CEO
    Steve Forte, CFO
    Donna Grogan, MD, CMO
    Jeff Packman, Chief Dev. Officer
  • Contact Info
  • Clementia Pharmaceuticals Inc.
    Phone: (514) 940-3600
    1000 de la Gauchetière O
    Ste. 1200
    Montreal, H3B 4W5
    Canada
UsernamePublicRestriction

Register